{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:59:40Z","timestamp":1788263980747,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T00:00:00Z","timestamp":1301961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s10549-011-1461-y","type":"journal-article","created":{"date-parts":[[2011,4,4]],"date-time":"2011-04-04T10:32:38Z","timestamp":1301913158000},"page":"127-136","source":"Crossref","is-referenced-by-count":62,"title":["Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer"],"prefix":"10.1007","volume":"128","author":[{"given":"M.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C. U.","family":"Cheang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"L\u00f3pez Garc\u00eda-Asenjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Garc\u00eda-Saenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Furio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Cald\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Vidart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lopez-Tarruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Diaz-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Perou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,5]]},"reference":[{"key":"1461_CR1","doi-asserted-by":"crossref","unstructured":"Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists\u2019 Collaborative Group. Lancet 1998;352(9132):930\u2013942","DOI":"10.1016\/S0140-6736(98)03301-7"},{"key":"1461_CR2","doi-asserted-by":"crossref","unstructured":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687\u20131717","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"1461_CR3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","volume":"21","author":"IC Henderson","year":"2003","unstructured":"Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976\u2013983","journal-title":"J Clin Oncol"},{"key":"1461_CR4","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Bryant J, Lembersky BC et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for nodepositive breast cancer: results from NSABP-B 28. J Clin Oncol 23:3686\u20133696","journal-title":"J Clin Oncol"},{"key":"1461_CR5","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node positive breast cancer. N Engl J Med 352:2302\u20132313","journal-title":"N Engl J Med"},{"key":"1461_CR6","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","volume":"24","author":"H Roche","year":"2006","unstructured":"Roche H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PASC 01 Trial. J Clin Oncol 24:5664\u20135671","journal-title":"J Clin Oncol"},{"key":"1461_CR7","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","volume":"27","author":"S Jones","year":"2009","unstructured":"Jones S, Holmes FA, O\u2019Shaughnessy JO et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177\u20131183","journal-title":"J Clin Oncol"},{"key":"1461_CR8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/djn151","volume":"100","author":"M Martin","year":"2008","unstructured":"Martin M, Rodriguez-Lescure A, Ruiz A et al (2008) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100:805\u2013814","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1461_CR9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jnci\/djm287","volume":"100","author":"P Francis","year":"2008","unstructured":"Francis P, Crown J, Di Leo A et al (2008) Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 100(2):121\u2013133","journal-title":"J Natl Cancer Inst"},{"key":"1461_CR10","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2008.19.2567","volume":"27","author":"L Gianni","year":"2009","unstructured":"Gianni L, Baselga J, Eiermann W (2009) Phase III trial valuating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 27:2474\u20132481","journal-title":"J Clin Oncol"},{"key":"1461_CR11","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1200\/JCO.2007.13.4429","volume":"26","author":"LJ Goldstein","year":"2008","unstructured":"Goldstein LJ, O\u2019Neill A, Sparano JA et al (2008) Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 26:4078\u20134085","journal-title":"J Clin Oncol"},{"key":"1461_CR12","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0140-6736(09)60740-6","volume":"373","author":"P Ellis","year":"2009","unstructured":"Ellis P, Barrett-Lee P, Johnson L et al (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 373:1681\u20131692","journal-title":"Lancet"},{"key":"1461_CR13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747\u2013752","journal-title":"Nature"},{"key":"1461_CR14","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869\u201310874","journal-title":"Proc Natl Acad Sci USA"},{"key":"1461_CR15","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","volume":"100","author":"T Sorlie","year":"2003","unstructured":"Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418\u20138423","journal-title":"Proc Natl Acad Sci USA"},{"key":"1461_CR16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"MA Cheang","year":"2009","unstructured":"Cheang MA, Chia SK, Vodue D et al (2009) Ki67 index, HERT2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736\u2013750","journal-title":"J Natl Cancer Inst"},{"key":"1461_CR17","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","volume":"13","author":"L Carey","year":"2007","unstructured":"Carey L, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329\u20132334","journal-title":"Clin Cancer Res"},{"key":"1461_CR18","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","volume":"11","author":"R Rouzier","year":"2005","unstructured":"Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678\u20135685","journal-title":"Clin Cancer Res"},{"key":"1461_CR19","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414\u20134422","journal-title":"J Clin Oncol"},{"key":"1461_CR20","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160\u20131167","journal-title":"J Clin Oncol"},{"key":"1461_CR21","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/bcr2635","volume":"12","author":"A Prat","year":"2010","unstructured":"Prat A, Parker J, Karginova O et al (2010) Phenotyphic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68","journal-title":"Breast Cancer Res"},{"key":"1461_CR22","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2008.18.1024","volume":"27","author":"J Hugh","year":"2009","unstructured":"Hugh J, Hanson J, Cheang MCU et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 Trial. J Clin Oncol 27:1168\u20131176","journal-title":"J Clin Oncol"},{"key":"1461_CR23","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1016\/j.ejca.2006.06.013","volume":"42","author":"E Arriola","year":"2006","unstructured":"Arriola E, Moreno A, Varela M et al (2006) Predictive value of HER-2 and topoisomerase II\u03b1 in response to primary doxorubicin in breast cancer. Eur J Cancer 42:2954\u20132960","journal-title":"Eur J Cancer"},{"key":"1461_CR24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-005-9020-z","volume":"94","author":"YL Tham","year":"2005","unstructured":"Tham YL, Gomez LF, Mohsin S et al (2005) Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancer. Breast Cancer Res Treat 94:279\u2013284","journal-title":"Breast Cancer Res Treat"},{"key":"1461_CR25","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/annonc\/mdi254","volume":"16","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Wedam SB, Jahanzeb M et al (2005) Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 16:1297\u20131304","journal-title":"Ann Oncol"},{"key":"1461_CR26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/jnci\/djp092","volume":"101","author":"DJ Slamon","year":"2009","unstructured":"Slamon DJ, Press MF (2009) Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst 101:615\u2013619","journal-title":"J Natl Cancer Inst"},{"key":"1461_CR27","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa054504","volume":"354","author":"KI Pritchard","year":"2006","unstructured":"Pritchard KI, Shepherd LE, O\u2019Malley FP et al (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103\u20132111","journal-title":"N Engl J Med"},{"key":"1461_CR28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djm252","volume":"100","author":"A Gennari","year":"2008","unstructured":"Gennari A, Sormani MP, Pronzato P et al (2008) HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100:14\u201320","journal-title":"J Natl Cancer Inst"},{"key":"1461_CR29","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/cncr.11245","volume":"97","author":"F Zhang","year":"2003","unstructured":"Zhang F, Yang Y, Smith T et al (2003) Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluororuacil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97:1758\u20131765","journal-title":"Cancer"},{"key":"1461_CR30","first-page":"1319","volume":"22","author":"F Penault-Llorca","year":"2003","unstructured":"Penault-Llorca F, Cayre A, Bouchet Mishellany F et al (2003) Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 22:1319\u20131325","journal-title":"Int J Oncol"},{"key":"1461_CR31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0959-8049(03)00675-0","volume":"40","author":"T Petit","year":"2004","unstructured":"Petit T, Wilt M, Velten M et al (2004) Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205\u2013211","journal-title":"Eur J Cancer"},{"key":"1461_CR32","first-page":"2505","volume":"61","author":"S Geisler","year":"2001","unstructured":"Geisler S, L\u01ffnning PE, Aas T et al (2001) Influence of TP53 gene alterations and c-erbB2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61:2505\u20132512","journal-title":"Cancer Res"},{"key":"1461_CR33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/B:BREA.0000036783.88387.47","volume":"86","author":"A Di Leo","year":"2004","unstructured":"Di Leo A, Chan S, Paesmans M et al (2004) HE2\/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 86:197\u2013206","journal-title":"Breast Cancer Res Treat"},{"key":"1461_CR34","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/bjc.1998.377","volume":"77","author":"TAH J\u00e4rvinen","year":"1998","unstructured":"J\u00e4rvinen TAH, Holli K, Kuukasj\u00e4rvi T, Isola JJ (1998) Predictive value of topoisomerase II\u03b1 and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 77:2267\u20132273","journal-title":"Br J Cancer"},{"key":"1461_CR35","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2009.22.6449","volume":"27","author":"F Esteva","year":"2009","unstructured":"Esteva F, Hortobagyi GN (2009) Topoisomerase II\u03b1 amplification and anthracycline-based chemotherapy: the jury is still out. J Clin Oncol 27:3416\u20133417","journal-title":"J Clin Oncol"},{"key":"1461_CR36","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1200\/JCO.2009.22.8361","volume":"27","author":"KI Pritchard","year":"2009","unstructured":"Pritchard KI (2009) Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer? J Clin Oncol 27:3875\u20133876","journal-title":"J Clin Oncol"},{"key":"1461_CR37","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1200\/JCO.2008.20.1640","volume":"27","author":"L Gianni","year":"2009","unstructured":"Gianni L, Valagussa P (2009) Anthracyclines and early breast cancer: the end of an era? J Clin Oncol 27:1155\u20131157","journal-title":"J Clin Oncol"},{"key":"1461_CR38","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1200\/JCO.2006.05.9113","volume":"24","author":"AU Buzdar","year":"2006","unstructured":"Buzdar AU (2006) Topoisomerase II\u03b1 gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. J Clin Oncol 24:2409\u20132411","journal-title":"J Clin Oncol"},{"key":"1461_CR39","first-page":"1061","volume":"8","author":"JS Coon","year":"2002","unstructured":"Coon JS, Marcus E, Gupta-Burt S et al (2002) Amplification and overexpression of topoisomerase II\u03b1 predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8:1061\u20131067","journal-title":"Clin Cancer Res"},{"key":"1461_CR40","first-page":"201","volume":"24","author":"F Cardoso","year":"2004","unstructured":"Cardoso F, Durbecq V, Larsimont D et al (2004) Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II\u03b1 gene amplification and protein expression in locally advanced breast cancer. Int J Oncol 24:201\u2013209","journal-title":"Int J Oncol"},{"key":"1461_CR41","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1200\/JCO.2005.11.007","volume":"23","author":"AS Knoop","year":"2005","unstructured":"Knoop AS, Knudsen H, Basley E et al (2005) Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive marker in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483\u20137490","journal-title":"J Clin Oncol"},{"key":"1461_CR42","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2005.02.9264","volume":"24","author":"M Tanner","year":"2006","unstructured":"Tanner M, Isola J, Wiklund T et al (2006) Topoisomerase II-alpha gene amplification predicts favourable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2\/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24:2428\u20132436","journal-title":"J Clin Oncol"},{"key":"1461_CR43","first-page":"1107","volume":"8","author":"A Di Leo","year":"2002","unstructured":"Di Leo A, Gancberg D, Larsimont D et al (2002) HER-2 amplification and topoisomerase II\u03b1 gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8:1107\u20131116","journal-title":"Clin Cancer Res"},{"key":"1461_CR44","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0959-8049(02)00745-1","volume":"39","author":"K Park","year":"2003","unstructured":"Park K, Kim J, Lim S, Han S (2003) Topoisomerase II-\u03b1 (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39:631\u2013634","journal-title":"Eur J Cancer"},{"key":"1461_CR45","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1200\/JCO.2008.20.1566","volume":"27","author":"R Tubbs","year":"2009","unstructured":"Tubbs R, Barlow WE, Budd T et al (2009) Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 27:3881\u20133886","journal-title":"J Clin Oncol"},{"key":"1461_CR46","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/jnci\/djp067","volume":"101","author":"FP O\u2032Malley","year":"2009","unstructured":"O\u2032Malley FP, Chia S, Tu D et al (2009) Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101:644\u2013650","journal-title":"J Natl Cancer Inst"},{"key":"1461_CR47","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.2008.18.4085","volume":"27","author":"LN Harris","year":"2009","unstructured":"Harris LN, Broadwater G, Abu-Khalaf M et al (2009) Topoisomerase II\u03b1 amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER-2amplified early breast cancer: results of CALGB 8541\/150013. J Clin Oncol 27:3430\u20133436","journal-title":"J Clin Oncol"},{"key":"1461_CR48","doi-asserted-by":"crossref","unstructured":"Desmedt C, E. Azambuja E, Larsimont D et al (2009) Predicting the efficacy of anthracyclines in breast cancer (BC) patients: results of the neoadjuvant TOP trial. J Clin Oncol 27:15S (Abstr. 523)","DOI":"10.1200\/jco.2009.27.15_suppl.523"},{"key":"1461_CR49","first-page":"1473","volume":"25","author":"V Durbecq","year":"2004","unstructured":"Durbecq V, Desmedt C, Paesmans M et al (2004) Correlation between topoisomerase II\u03b1 (Topo-II) gene amplification and protein expression in her-2 amplified breast cancer patients. Int J Oncol 25:1473\u20131479","journal-title":"Int J Oncol"},{"key":"1461_CR50","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/gcc.20008","volume":"39","author":"RE Mueller","year":"2004","unstructured":"Mueller RE, Parkes RK, Androlis J (2004) O\u2032Malley FP. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 39:288\u2013297","journal-title":"Genes Chromosomes Cancer"},{"key":"1461_CR51","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/1535-7163.1207.3.10","volume":"3","author":"V Durbecq","year":"2004","unstructured":"Durbecq V, Paesmans M, Cardoso F et al (2004) Topoisomerase-II\u03b1 expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 3:1207\u20131214","journal-title":"Mol Cancer Ther"},{"key":"1461_CR52","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1023\/A:1011669223035","volume":"12","author":"A Di Leo","year":"2001","unstructured":"Di Leo A, Larsimont D, Gancberg D et al (2001) HER-2 and topo-isomerase II\u03b1 as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 12:1081\u20131089","journal-title":"Ann Oncol"},{"key":"1461_CR53","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1349-7006.2006.00265.x","volume":"97","author":"S Noguchi","year":"2006","unstructured":"Noguchi S (2006) Predictive factors for response to docetaxel in human breast cancer. Cancer Sci 97:813\u2013820","journal-title":"Cancer Sci"},{"issue":"Suppl 12","key":"1461_CR54","first-page":"xii15","volume":"18","author":"L Pustzai","year":"2007","unstructured":"Pustzai L (2007) Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol 18(Suppl 12):xii15\u2013xii20","journal-title":"Ann Oncol"},{"key":"1461_CR55","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/cncr.20348","volume":"101","author":"A Gonzalez-Angulo","year":"2004","unstructured":"Gonzalez-Angulo A, Krishnamurthy S, Broglio KR et al (2004) Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 101:258\u2013263","journal-title":"Cancer"},{"key":"1461_CR56","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/cncr.21037","volume":"103","author":"PA Learn","year":"2005","unstructured":"Learn PA, Yeh IT, McNutt M et al (2005) HER2\/neu expression as predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer 103:2252\u20132260","journal-title":"Cancer"},{"key":"1461_CR57","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-07-4741","volume":"14","author":"CM Galmarini","year":"2008","unstructured":"Galmarini CM, Treilleux I, Cardoso F et al (2008) Class III \u03b2-tubulin isotype predicts response in adjuvant breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 14:4511\u20134516","journal-title":"Clin Cancer Res"},{"key":"1461_CR58","first-page":"2992","volume":"9","author":"S Hasegawa","year":"2003","unstructured":"Hasegawa S, Miyoshi Y, Egawa C et al (2003) Prediction of response to docetaxel by quantitative analysis of class I and III \u03b2-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 9:2992\u20132997","journal-title":"Clin Cancer Res"},{"key":"1461_CR59","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3816\/CBC.2002.n.037","volume":"3","author":"C Bernard-Marty","year":"2002","unstructured":"Bernard-Marty C, Treilleux I, Dumontet C et al (2002) Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Cancer Breast 3:341\u2013345","journal-title":"Clin Cancer Breast"},{"key":"1461_CR60","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1200\/JCO.2008.18.2808","volume":"27","author":"F Pernault-Llorca","year":"2009","unstructured":"Pernault-Llorca F, Andr\u00e9 F, Sagan C et al (2009) Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2809\u20132815","journal-title":"J Clin Oncol"},{"key":"1461_CR61","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00432-007-0319-5","volume":"134","author":"Y Miyoshi","year":"2008","unstructured":"Miyoshi Y, Kurosumi M, Kurebayashi J et al (2008) Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancer. J Cancer Res Clin Oncol 134:561\u2013567","journal-title":"J Cancer Res Clin Oncol"},{"key":"1461_CR62","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E et al (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185\u2013229","journal-title":"Pharmacol Rev"},{"key":"1461_CR63","doi-asserted-by":"crossref","unstructured":"Cheang M, Chia SK, Tu D et al (2009) Anthracyclines in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 27:15S (Abstr. 519)","DOI":"10.1200\/jco.2009.27.15_suppl.519"},{"key":"1461_CR64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-009-0663-z","volume":"123","author":"M Mart\u00edn","year":"2010","unstructured":"Mart\u00edn M, Rodr\u00edguez-Lescure A, Ruiz A et al (2010) Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat 123:149\u2013157","journal-title":"Breast Cancer Res Treat"},{"key":"1461_CR65","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/bcr1982","volume":"10","author":"CM Fillmore","year":"2008","unstructured":"Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10:R25","journal-title":"Breast Cancer Res"},{"key":"1461_CR66","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.humpath.2009.08.023","volume":"41","author":"S Aulmann","year":"2010","unstructured":"Aulmann S, Waldburger N, Penzel R, Andrulis M, Schirmacher P, Sinn HP (2010) Reduction of CD44+\/CD24\u2212 breast cancer cells by conventional cytotoxic chemotherapy. Hum Pathol 41:574\u2013581","journal-title":"Hum Pathol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1461-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-011-1461-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1461-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:59:55Z","timestamp":1686013195000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-011-1461-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,5]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["1461"],"URL":"https:\/\/doi.org\/10.1007\/s10549-011-1461-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,5]]}}}